Chengdu Easton Biopharmaceuticals Co Ltd
Chengdu Easton Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, and commercialization of pharmaceutical products. The company provides finished dosage forms comprising capsules, tablets, and injections, as well as active pharmaceutical ingredients (API). It also offers API products, such as Apixaban for cardiovascular applications; A… Read more
Chengdu Easton Biopharmaceuticals Co Ltd (688513) - Total Liabilities
Latest total liabilities as of September 2025: CN¥692.94 Million CNY
Based on the latest financial reports, Chengdu Easton Biopharmaceuticals Co Ltd (688513) has total liabilities worth CN¥692.94 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Chengdu Easton Biopharmaceuticals Co Ltd - Total Liabilities Trend (2013–2024)
This chart illustrates how Chengdu Easton Biopharmaceuticals Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Chengdu Easton Biopharmaceuticals Co Ltd Competitors by Total Liabilities
The table below lists competitors of Chengdu Easton Biopharmaceuticals Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Engie Energia Chile SA
SN:ECL
|
Chile | CL$2.96 Billion |
|
First National of Nebraska Inc
PINK:FINN
|
USA | $28.99 Billion |
|
AMN Healthcare Services Inc
NYSE:AMN
|
USA | $1.49 Billion |
|
Shenzhen Anche Technologies Co Ltd
SHE:300572
|
China | CN¥676.40 Million |
|
Hefei Jianghang Aircraft Equipment Corporation Ltd
SHG:688586
|
China | CN¥1.14 Billion |
|
Ticon Freehold and Leasehold Real Estate Investment Trust
BK:FTREIT
|
Thailand | ฿16.67 Billion |
|
Arvind Limited
NSE:ARVIND
|
India | ₹43.03 Billion |
|
KBC Corporation Ltd
SHG:688598
|
China | CN¥1.07 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down Chengdu Easton Biopharmaceuticals Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.50 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Chengdu Easton Biopharmaceuticals Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Chengdu Easton Biopharmaceuticals Co Ltd (2013–2024)
The table below shows the annual total liabilities of Chengdu Easton Biopharmaceuticals Co Ltd from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥702.21 Million | -5.53% |
| 2023-12-31 | CN¥743.33 Million | +29.71% |
| 2022-12-31 | CN¥573.08 Million | +18.50% |
| 2021-12-31 | CN¥483.60 Million | +11.02% |
| 2020-12-31 | CN¥435.61 Million | +50.40% |
| 2019-12-31 | CN¥289.64 Million | +39.58% |
| 2018-12-31 | CN¥207.50 Million | +41.45% |
| 2017-12-31 | CN¥146.70 Million | +12.48% |
| 2016-12-31 | CN¥130.43 Million | +200.42% |
| 2015-12-31 | CN¥43.42 Million | -45.63% |
| 2014-12-31 | CN¥79.85 Million | -7.42% |
| 2013-12-31 | CN¥86.24 Million | -- |